Kura Oncology, Inc. (KURA) – What Are Investment Firms Thinking About This Stock?

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have received an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $25.35.

A number of equities analysts recently commented on KURA shares. Raymond James Financial set a $24.00 price target on shares of Kura Oncology in a research note on Monday, August 24th. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research note on Wednesday, October 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, October 14th. Citizens Jmp restated a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research report on Monday, August 24th. Finally, Barclays set a $24.00 target price on Kura Oncology in a research note on Wednesday, October 14th.

Insider Buying and Selling

In other Kura Oncology news, insider Mollie Leoni sold 28,802 shares of the business’s stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total value of $309,621.50. Following the completion of the sale, the insider directly owned 141,095 shares of the company’s stock, valued at $1,516,771.25. The trade was a 16.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Troy Wilson acquired 100,000 shares of the stock in a transaction on Monday, August 17th. The stock was bought at an average cost of $11.12 per share, with a total value of $1,112,000.00. Following the completion of the transaction, the chief executive officer owned 379,194 shares in the company, valued at $4,216,637.28. This trade represents a 35.82% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 153,881 shares of company stock worth $1,708,183 over the last ninety days. 7.60% of the stock is owned by insiders.

Institutional Trading of Kura Oncology

Several institutional investors and hedge funds have recently modified their holdings of the stock. Royce & Associates LP grew its stake in Kura Oncology by 8.0% in the third quarter. Royce & Associates LP now owns 658,811 shares of the company’s stock worth $7,056,000 after purchasing an additional 48,826 shares in the last quarter. ACT Capital Partners L.P. purchased a new position in Kura Oncology during the 3rd quarter worth $981,000. Aberdeen Group plc bought a new stake in Kura Oncology during the 3rd quarter valued at $8,443,000. Russell Investments Group Ltd. raised its position in Kura Oncology by 88.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 213,447 shares of the company’s stock valued at $2,286,000 after purchasing an additional 100,364 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its position in Kura Oncology by 22.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 14,412 shares of the company’s stock valued at $154,000 after purchasing an additional 2,656 shares in the last quarter.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $7.57 on Thursday. The stock’s fifty day moving average is $10.60 and its 200 day moving average is $9.79. Kura Oncology has a fifty-two week low of $6.75 and a fifty-two week high of $13.90. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The company had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. As a group, equities research analysts forecast that Kura Oncology will post -3.25 earnings per share for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options.

Kura’s lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements.